
Opinion|Videos|April 4, 2025
Payer and Reimbursement Considerations for Bispecific Therapies
Experts discuss how payer and reimbursement considerations affect access to bispecific therapies in different practice settings.
Advertisement
Episodes in this series

Video content above is prompted by the following:
How do payer and reimbursement considerations affect access to bispecific therapies in different practice settings?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Mirvetuximab Soravtansine Demonstrates Promising Efficacy, Safety in Platinum-Resistant Recurrent Ovarian Cancer
2
How Artificial Intelligence Is Transforming Leukemia Detection and Diagnosis
3
Long-Term Remission in Ph-Negative B-ALL With Sequential CAR T, ASCT
4
Zanubrutinib Shows Similar Efficacy but Better Safety Than VEN–I in Frontline CLL
5














































